Medical Department I, Universitätsklinikum Marien Hospital Herne, Ruhr-University of Bochum, Germany.
Medical Department I, Universitätsklinikum Marien Hospital Herne, Ruhr-University of Bochum, Germany.
Transplant Proc. 2020 Dec;52(10):3192-3196. doi: 10.1016/j.transproceed.2020.06.018. Epub 2020 Jul 13.
Recurrent urinary tract infections (UTIs) increase mortality and reduce graft survival after renal transplantation. Because current prophylactic strategies such as methionine, cranberry juice, and antibiotics fail to sufficiently prevent recurrent infections in a substantial number of patients, there is a clinical need for alternative approaches. The present work describes first experiences with an immunization strategy against bacterial strains after kidney transplantation.
We performed a retrospective single-center analysis of an immunization approach against 10 strains of inactivated bacteria (StroVac). A total of 14 renal transplant recipients with 3 or more UTI episodes/year underwent immunization with 3 subcutaneous injections of inactivated bacteria (follow-up 12 months before to 12 months after immunization). These patients were compared to 14 renal transplant patients without immunization who were matched for number of UTIs and time after transplantation (24 months follow-up). We compared the UTI incidence and potential side effects, including development of de novo donor-specific antibodies (DSA).
The immunization significantly decreased the incidence of UTIs from 3.4 ± 1.3 to 0.9 ± 1.0 by 74.9%. The incidence did not change from year 1 to year 2 of the observation period in the control group. Immunization was tolerated well, without any clinical complaints. There were no de novo DSAs in the first year after immunization.
Immunization against inactivated bacterial strains substantially reduced the incidence of UTIs without eliciting any safety concerns in this small cohort of renal transplant recipients. This strategy may be a helpful expansion of our preventive measures in patients with recurrent UTIs.
复发性尿路感染(UTI)会增加肾移植后的死亡率并降低移植物存活率。由于目前的预防性策略,如蛋氨酸、蔓越莓汁和抗生素,无法在相当数量的患者中充分预防复发性感染,因此需要替代方法。本研究描述了肾移植后针对细菌株的免疫策略的初步经验。
我们对 10 株灭活细菌(StroVac)的免疫方法进行了回顾性单中心分析。共有 14 名每年发生 3 次或以上 UTI 的肾移植受者接受了 3 次皮下注射灭活细菌的免疫接种(免疫接种前 12 个月至免疫接种后 12 个月进行随访)。这些患者与未接受免疫接种的 14 名肾移植患者进行了比较,这些患者在 UTI 数量和移植后时间方面进行了匹配(随访 24 个月)。我们比较了 UTI 的发生率和潜在的副作用,包括新出现的供体特异性抗体(DSA)的发展。
免疫显著降低了 UTI 的发生率,从 3.4±1.3 降至 0.9±1.0,降幅为 74.9%。在对照组中,观察期的第 1 年到第 2 年,发病率没有变化。免疫接种耐受良好,没有任何临床不适。在免疫接种后的第一年没有新出现的 DSA。
针对灭活细菌株的免疫接种大大降低了 UTI 的发生率,而在这一小群肾移植受者中未引起任何安全问题。这种策略可能是我们对复发性 UTI 患者预防措施的有益扩展。